

Harnessing Nature to Improve Health



protoKinetix^{INC}
CELL SURVIVAL SOLUTIONS

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this presentation includes "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act"). All statements, other than statements of historical facts, included herein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. These forward looking statements are identified by their use of terms and phrases such as "may," "expect," "estimate," "project," "plan," "believe," "intend," "achievable," "anticipate," "will," "continue," "potential," "should," "could," and similar terms and phrases. Although we believe that the expectations reflected in these forward looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not be considered to be) guarantees of future performance. Among these risks are those set forth in a Form 10-K filed on March 12, 2019. It is important that each person attending this presentation understand the significant risks attendant to the operations of ProtoKinetix. ProtoKinetix disclaims any obligation to update any forward-looking statement made here.

This presentation does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, except pursuant to an exemption from or in a transaction not subject to the registration requirements of the Securities Act.



OTCQB: PKTX

Investor Presentation 2019

www.protokinetix.com



@ProtoKinetix



PKTX

Company Overview

- The company has a **lean R&D** operation with a focused platform utilizing key partnerships with Academic Brain Trusts and leading Pharmaceutical CROs to support commercialization.
- We are continuing to develop a family of nature-inspired **glycopeptides** to address medical market needs.
- The company has a focused strategic plan for **market entry** on key positions revealed by the pipeline of our R&D validation studies for our proprietary lead product, **PKX-001**.
- **PKX-001** has demonstrated **key market indications** for development in both high-volume & high-value sectors as an adjuvant medical device to **create optimal share value**.



PKTX

Key Market Indications

Ophthalmology (Eyes)



Dermatology (Skin)



Transplant Support
(Cells & Organs)



Biological Manufacturing
(mAB production)



PKTX

Addressable Market Values

Ophthalmology (Eyes)

\$4-6 Billion

Dry Eye Disease
Market with a
CAGR 7%

Dermatology (Skin)

\$44-82 Billion

Skin Care Market
(OTC & Rx) with a
CAGR 8-11%

Transplant Support

(Cells & Organs)

\$73-127 Billion

Organ Transplant
Market with a
CAGR 9-10%

Biological Manufacturing

(mAB production)


\$285-480 Billion

Biological Mftg.
Market with a
CAGR 7-11%



PKTX

Lead Compound



- PKX-001 is a **patent protected** small peptide molecule, that is produced entirely by synthetic chemistry methods.
- PKX-001 has demonstrated **therapeutic efficacy** via anti-inflammatory, anti-oxidant, anti-cold injury, & UV-protection.
- PKX-001 has a therapeutic range of 0.1 to 5mg/ml; is highly stable and has a five-fold **safety threshold** (non-toxic upto 25mg/ml)
- Compared to naturally occurring or biologically produced anti-freeze proteins, PKX-001 has relatively **low cost of goods** at 2-12%




PKTX

Market Indication



Dry eye disease impacts women more than men & has double digit % growth in emerging markets & in orphan diseases.



- The population affected is 7% (20% over 75yr) where nearly 17% of population is >65yr by 2050.
- Early market positioning in OTC dry eye disease and **veterinary treatment** for keratoconjunctivitis sicca in dogs could lead to revenue on an accelerated timeline than what is typical for human alone treatments.
- PKX-001 is protective in human retina cell transplant studies and these findings can be extended to elicit protection of surface lubricating cells commonly lost in dry eye disease with formulations of eye drops and lubricants – under the trademark **ArcticTears™**




PKTX

Market Indications




Whether applied before or after UV ray exposure, PKX-001 can both protect and rescue skin from UV damage.

Skin Cell **Protection**
From UV Rays (48hrs)



Skin Cell **Recovery**
After UV Rays (48hrs)







PKTX

Market Indication



Enhancing the Curative Potential for Type-1 Diabetes by Protecting Islet Cell Transplants.






PKTX


Market Indication




Maintenance of Stem Cell Marker



CryoRecovery of Hybridoma Cells (24hrs)



Total Anti-body Production After Cell Recovery (96hrs)



The bottom line for biological manufacturers could be a **3-5 fold gain in value production.**



PKTX

Clinical Academic Brain Trusts

- **Dr. James Shapiro**, Alberta Diabetes Institute, Founder of the Edmonton Protocol for T1D
- **Dr. Gregory Evans**, Julia Levy Chair in Ophthalmology
- **Dr. Mike Williams**, AbLab, UBC
- **Dr. Kelly McNagny**, CBR, UBC
- **Dr. Boris Gala-Lopez**, Dalhousie Transplantation Lab &
- **Dr. Thomas Pulinilkunnil**, IMPART investigator team Canada





PKTX

Pharmaceutical Partners

- AmbioPharma
(GCP Production & IP Partner)



- BRI & Nelson Laboratories (Quality Control Analytical)



- ITR Laboratories (Safety Pharmacology Testing)



- Iotron (GCP Medical Sterilization for Human Trials)



- **TBA** - (Special Product Formulations & Packaging), (GMP eye testing & validation) & *(Regulatory Affairs for GoToMarket)*

Perspective on the Lean R&D Company Go-To-Market Strategy

- Infrastructure
- Human Capital
- Leveraged Funding
- Ideation to Minimal Viable Products & Proof of Concept
- Passive Marketing
- Investigator Initiated Clinical Trials

**Brain
Trusts**

Slow
(\$)

CRO

Fast
(\$\$\$)

- Industry relations
- GMP/GCP Scaled Production
- Product Formulation & Regulatory Compliance
- Pharmaceutical Dynamics, Kinetics, & Tolerance Testing
- Sponsored Clinical Trials & Regulatory Compliance
- Active Marketing & Salesforce

Investors

Stable
\$\$\$

\$\$\$\$\$\$\$
Returns

protoKinetix INC.
CELL SURVIVAL SOLUTIONS

- General Operations
- Strategic Directions
- Technology & IP Portfolio
- Exchange Filing & Reporting
- Secure Shareholder Interests
- Elevate Share Value (Buy Back)

Returns
\$\$\$\$\$\$\$

Acquisition x **25**

Market

- OTC & Rx Eye Drops – **Arctic Tears**
- OTC & Rx Skin Care – **Arctic Balm**
- Manufacturing Adjuvant – **BiostimAB**
- InHospital Medical Device – **CytoproTx**

**In Market Big Cap
Corporate Partners &
Potential Acquirers**



PKTX

Corporate Strategy

Near term Objectives & Milestones (Next 12-24 Months)

- Identify and secure specialized formulations CRO partner(s) familiar with **meeting OTC & Rx regulatory requirements** to position for market entry and revenue generation.
 - Determine suitability and partner with a Brain Trust (OVC or PEI) for early market entry & traction in Rx-Veterinary Medicine.
- Expand upon success in **human clinical trials** with PKX-001 in Islet (extended Phase-1 & Phase-2a) & in Retinal Cell Transplantation Studies with Brain Trusts & CRO.
- Identify a Brain Trust & CRO (NRC/BioVectra) to develop large at scale protocols that **buildout a milestone based investment project** with a large multi-national Biologic Manufacturer.
- Continue pipeline research with an expanded ischemic disease portfolio application to: kidney, heart, liver, and brain.



PKTX

Investment Highlight

- **Exclusive** secured composition of matter IP and trade secret synthetic chemistry manufacturing process that is rapidly scalable.
- A **capacity** for expanded patent securities through pipeline product formulations, in/out licensing, and registrations for orphan disease designations with the FDA.
- Well **positioned for revenue based growth**, maintaining debt free lean R&D pipeline channels that are both **high-volume** in the OTC and BioManufacturing sectors and **high-value** Rx & Hospital transplant therapy support.
- Positioning well for **rapid market penetration** by serving needs in the OTC and veterinary medicine sectors.
- **Equity value** of \$32-37Million* is compelling with interest expected to grow from licensing and milestone partnership developments.
- Delivery of products to serve unmet medical needs and value added production and **capitalizing on new opportunities** in the regenerative medicine and biomanufacturing sectors.



PKTX

Leadership



Clarence E. Smith (55yr), CEO & President – a serial entrepreneur with 38years of expertise of executive business management from inception to development, acquisitions, and mergers. Serving on the Board of Directors for 5-years and currently an activist owner collecting \$1/yr salary and major shareholder.



Michael R. Guzzeta (61yr), CFO – a Certified Public Accountant specialized in corporate development & organization with 20yrs experience in corporate management, banking, and risk mitigation. Previous fortune 100 company manager and Adjunct Professor at Stark College of Business Faculty.



Grant Young (70yr), Founder & Medical Science Liaison – Managed the last 12 years to establish the current product portfolio based intellectual property. With 20years of biotechnology venture development he continues to direct brain trusts and supply chain management, specializing in partnerships and lean operations & direct clinical trial activities.

The executive team is guided by advisors and directors and fully supported by expert scientific & medical consultants, industrial relations & investment banking organizations, intellectual property & legal counsel.



PKTX

Stock Snapshot (June 1, 2019)



**\$37 Million
Mkt Cap**

\$0.15/share


+45% SMA200

**28% Insider
Ownership**



PKTX

Contact Information



ProtoKinetix Inc. 412 Mulberry St.

Marietta, Ohio, 45750

<http://www.protokinetix.com/>

@ProtoKinetix

ProtoKinetix Inc. Cell Survival Solutions

OTC: PKTX

@ProtoKinetix

www.protokinetix.com

Confidentiality Statement

The information contained herein is confidential and the proprietary property of ProtoKinetix, Inc. Any unauthorized use or disclosure of such information without the prior written authorization of ProtoKinetix, Inc. is prohibited.